TW239869B - - Google Patents

Download PDF

Info

Publication number
TW239869B
TW239869B TW081105670A TW81105670A TW239869B TW 239869 B TW239869 B TW 239869B TW 081105670 A TW081105670 A TW 081105670A TW 81105670 A TW81105670 A TW 81105670A TW 239869 B TW239869 B TW 239869B
Authority
TW
Taiwan
Prior art keywords
compound
annexin
conjugate
item
patent application
Prior art date
Application number
TW081105670A
Other languages
English (en)
Chinese (zh)
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of TW239869B publication Critical patent/TW239869B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153Streptokinase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721Lipocortins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW081105670A 1991-05-09 1992-07-17 TW239869B (enrdf_load_stackoverflow)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69736491A 1991-05-09 1991-05-09

Publications (1)

Publication Number Publication Date
TW239869B true TW239869B (enrdf_load_stackoverflow) 1995-02-01

Family

ID=24800848

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081105670A TW239869B (enrdf_load_stackoverflow) 1991-05-09 1992-07-17

Country Status (5)

Country Link
EP (1) EP0538459A4 (enrdf_load_stackoverflow)
JP (1) JPH05508664A (enrdf_load_stackoverflow)
CA (1) CA2086437A1 (enrdf_load_stackoverflow)
TW (1) TW239869B (enrdf_load_stackoverflow)
WO (1) WO1992019279A1 (enrdf_load_stackoverflow)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178476A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
JP3664727B2 (ja) * 1994-01-24 2005-06-29 ネオルクス コーポレイション 放射標識したアネキシン
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
EP0765166B1 (en) * 1994-06-16 2003-05-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
EP1364964A1 (en) * 1994-06-16 2003-11-26 Neorx Corporation Radiolabeled annexingalactose conjugates
JPH10512852A (ja) * 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
WO1996017618A1 (en) * 1994-12-07 1996-06-13 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
NZ500598A (en) 1997-04-30 2001-09-28 Univ Washington Method of imaging cell death in vivo by administering annexin V labelled with a biocompatible radionuclide (technetium 99 m Tc99m) and measuring the gamma radiation emitted
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
FR2784106B1 (fr) * 1998-10-02 2002-04-19 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
WO2002067857A2 (en) 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
JP2004535375A (ja) 2001-04-03 2004-11-25 テセウス イメージング コーポレーション 生体内における細胞死の検出および随伴する症状の治療のためのアネキシンの使用方法
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
FR2841558B1 (fr) 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
FR2841557B1 (fr) * 2002-07-01 2005-12-09 Commissariat Energie Atomique Peptides ayant une affinite pour un phospholipide et utilisations
FR2856069A1 (fr) * 2003-06-10 2004-12-17 Bionexis Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
WO2018053597A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
WO1992005749A1 (en) * 1990-10-04 1992-04-16 New England Deaconess Hospital Corporation Soluble thrombogenesis inhibitor conjugates

Also Published As

Publication number Publication date
WO1992019279A1 (en) 1992-11-12
JPH05508664A (ja) 1993-12-02
EP0538459A4 (en) 1993-06-16
EP0538459A1 (en) 1993-04-28
CA2086437A1 (en) 1992-11-10

Similar Documents

Publication Publication Date Title
TW239869B (enrdf_load_stackoverflow)
US5632986A (en) Phospholipid-targeted thrombolytic agents
TW538048B (en) A soluble derivative of a soluble polypeptide and its use
RU2466141C2 (ru) МОДИФИЦИРОВАННЫЙ КОАГУЛИРУЮЩИЙ ФАКТОР VIIa С ПРОДЛЕННЫМ ВРЕМЕНЕМ ПОЛУЖИЗНИ
TW587081B (en) Vitamin K-dependent polypeptide with enhanced membrane binding affinity, protein C or activated protein C polypeptide, and pharmaceutical composition thereof
US5011686A (en) Thrombus specific conjugates
CN101405017A (zh) 具有磷脂酰丝氨酸结合结构域的嵌合蛋白
JPH05508766A (ja) フィブリン結合ドメインポリペプチド及びその使用,並びにその製造方法
CN113289009B (zh) 长效凝固因子及其产生方法
US20140248686A1 (en) Therapeutic polypeptides with increased in vivo recovery
MX2010010759A (es) Mutantes de estreptocinasa y sus formas covalentemente modificadas.
JP2015501137A (ja) 止血を調節するための組成物および方法
US5474766A (en) Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
JPH05506646A (ja) ヒト・フォンビルブラント因子のクローニング及び製造、並びにその使用方法
JPH10505502A (ja) 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法
JPH04505554A (ja) 可溶性トロンボモジュリン類似体
Jing et al. An αIIbβ3-and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis
WO2002014369A9 (en) Human kininogen d5 domain polypeptides and their use
US20030082740A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
JP3095771B2 (ja) ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法
MIRZA jllafiter of $ l| ilofl (oplip
EP2504027A1 (en) Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors
Speziale The thiols in platelet thrombospondin: evidence of intramolecular thiol-disulfide exchange
HK1129421B (en) Modified coagulation factor vila with extended half-life
AU2012258466A1 (en) Modified coagulation Factor VIIa with extended half-life